




TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX


Inventor: Khan et al.

Serial No.: 10/029,206


Docket No.: 2183-5222US

1/39

**Fig. 1****Fig. 2**




**MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS  
(EX VIVO)**



**Fig. 3**

**BONE MARROW CELL YIELD (IN VITRO)**




**Fig. 4**

+


**TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX**

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

**3/39**




**BONE MARROW CELL YIELD (IN VITRO)**



**Fig. 5**


**BONE MARROW CELL YIELD (IN VITRO)**



**Fig. 6**

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAXInventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

4/39



## BONE MARROW CELL YIELD (IN VITRO)




Fig. 7



MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS  
(IN VITRO)

Fig. 8


TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

5/39




**MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS  
(IN VITRO)**



**Fig. 9**

**MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS  
(IN VITRO)**




**Fig. 10**


**TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX**

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

**6/39**




**MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS  
(IN VITRO)**



**Fig. 11**


**'UNATTACHED' BONE MARROW CELL YIELD  
(EX VIVO)**




**Fig. 12**

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX  
Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US


7/39



**'UNATTACHED' BONE MARROW CELL YIELD  
(EX VIVO)**


**Fig. 13**

**'ATTACHED' BONE MARROW CELL YIELD  
(EX VIVO)**


**Fig. 14**

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX  
Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

8/39




**'ATTACHED' BONE MARROW CELL YIELD  
(EX VIVO)**



**Fig. 15**

**'UNATTACHED' BONE MARROW CELL YIELD  
(IN VITRO-NOD)**




**Fig. 16**




**TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX**

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

**9/39**



**'ATTACHED' BONE MARROW CELL YIELD  
(IN VITRO-NOD)**



**TREATMENT**

**Fig. 17**

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US

10/39





Fig. 19




Fig. 18

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

11/39





Fig. 21




Fig. 20

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

12/39





Fig. 23




Fig. 22





Fig. 25








Fig. 24



TREATMENT

Fig. 26



TREATMENT

Fig. 27

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

16/39

+





Fig. 28

+



TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

17/39







Fig. 29

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

18/39



TREATMENT

Fig. 30

4,183,522 US 2003-07-10

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX  
Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

19/39





Fig. 31

+

# TITLE: OLIGOPEPTIDE TREATMENT OF

ANTHRAX

Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US

20/39






Fig. 32

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

21/39

+



Stand#5-69 RT:  
0.75-0.96 AV.9 NL:  
1.28E7F+pFull ms1  
[200.00-2000.00]

Stand#4-68 RT:  
0.26-0.74 AV.41 NL:  
5.74E6F+pFull ms2  
416.30@80.00  
[110.00-420.00]

Stand#1 RT:0.01 AV.  
1 NL: 1.57E6F+pFull  
ms3 416.30@80.00  
242.00@80.00  
[65.00-420.00]

MSn Analysis of NMPF-4 peptide





Fig. 33

+

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

22/39



Fraction from nuclear extract of LPS stimulated RAW264.7 cells





Fig. 34

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

23/39



Fraction from nuclear extract of NMP-4+LPS stimulated RAW264.7 cells

lps-NAK4-push #82-145 RT: 0.57-1.00 AV:64 NL:3.69E5  
F:ip Full ms [300.00-500.00]






Fig. 35

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

24/39



Heart-rate (beats per minute) of R1429 during sepsis





Fig. 36



TITLE: OLIGOPEPTIDE TREATMENT OF  
 ANTHRAX  
 Inventor: Khan et al.  
 Serial No.: 10/029,206  
 Docket No.: 2183-5222US

25/39



Blood pressure (mmHg) of Ri429 during sepsis without treatment





Fig. 37

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX  
Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

26/39



Systolic-Diastolic bp of Ri429 during sepsis without treatment





Fig. 38

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

27/39



SpO<sub>2</sub> of Ri429 during sepsis without treatment





Fig. 39

28/39

+



Heart-rate (beats per minute) of Ri459 during sepsis





Fig. 40

+

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

29/39



Blood pressure (mmHg) of Ri459 during sepsis and treatment with NMPF





Fig. 41

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

30/39



Systolic- Diastolic bp of Ri459 during treatment with NMPF





Fig. 42

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

31/39



SpO<sub>2</sub> of Ri459 during sepsis and treatment with NMPF





Fig. 43

32/39



Heart-rate (beats per minute) of Ri427 during sepsis




Fig. 44




TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US



33/39

Blood pressure (mmHg) of Ri427 during sepsis and treatment with NMPF





Fig. 45



34/39

Systolic-Diastolic bp of Ri427 during treatment with NMPF





Fig. 46



SpO<sub>2</sub> of Ri459 during sepsis and treatment with NMPF





Fig. 47

+



36/39




Fig. 48A




Fig. 48B




Fig. 48C

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX

Inventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

37/39





Fig. 49A




Fig. 49B




Fig. 49C



TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAX


Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US

38/39

**Fig. 50**

TITLE: OLIGOPEPTIDE TREATMENT OF  
ANTHRAXInventor: Khan et al.  
Serial No.: 10/029,206  
Docket No.: 2183-5222US

39/39

## GTT




Fig. 51A

## Blood Glucose (Fasting)




Fig. 51B